

Jonathan Stutters

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6774571/publications.pdf>

Version: 2024-02-01

11
papers

339
citations

933447

10
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

509
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 429-440.	3.0	40
2	Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2022, 98, .	1.1	31
3	Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis. <i>NeuroImage: Clinical</i> , 2022, 35, 103048.	2.7	17
4	Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 995-1006.	1.9	20
5	Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. <i>Lancet Neurology</i> , The, 2021, 20, 709-720.	10.2	44
6	NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study. <i>American Journal of Neuroradiology</i> , 2020, 41, 2209-2218.	2.4	10
7	Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. <i>Lancet Neurology</i> , The, 2020, 19, 214-225.	10.2	81
8	Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-72.	0.7	11
9	Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. <i>BMJ Open</i> , 2018, 8, e021944.	1.9	43
10	Functional specialization and generalization for grouping of stimuli based on colour and motion. <i>NeuroImage</i> , 2013, 73, 156-166.	4.2	24
11	A brain-derived metric for preferred kinetic stimuli. <i>Open Biology</i> , 2012, 2, 120001.	3.6	18